Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,032 across all filing types
Latest filing 2018-06-27 Proxy Solicitation & In…
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Form of Proxy
Proxy Solicitation & Information Statement Classification · 98% confidence The document is explicitly titled 'Syncona Limited Form of Proxy' and contains instructions for shareholders on how to appoint a proxy to vote on their behalf at the '2018 Annual General Meeting'. A Form of Proxy is a key document used to solicit shareholder votes ahead of a general meeting, which falls directly under the definition of Proxy Solicitation & Information Statement (PSI). It is not the AGM presentation itself (AGM-R), nor is it a general report like a 10-K or IR.
2018-06-27 English
Syncona Limited - Autolus closes IPO
Capital/Financing Update Classification · 98% confidence The document is a press release from Syncona Limited announcing that its portfolio company, Autolus Therapeutics plc, has closed its Initial Public Offering (IPO) in the United States. An IPO is a primary method of raising capital and changing the capital structure of a company, often involving the issuance of new shares or the sale of existing shares to the public. This directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers fundraising and capital structure changes. Although it relates to an offering, it is an announcement of the completion of the financing event, not a general regulatory filing (RNS) or a detailed report.
2018-06-26 English
Syncona Limited - Autolus update on IPO
Share Issue/Capital Change Classification · 99% confidence The document is an announcement from Syncona Limited regarding its portfolio company, Autolus Therapeutics plc, pricing its Initial Public Offering (IPO) in the United States. Key phrases include 'Autolus update on IPO', 'announced the pricing of its initial public offering (“IPO”)', and details about the offering price and proceeds. This clearly relates to a significant financing or capital structure event for a portfolio company, which falls under the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but specifically details a fundraising/listing event.
2018-06-22 English
Syncona Limited - Syncona makes £85 million commitment to Freeline
Regulatory Filings Classification · 99% confidence The document is a press release announcing a significant financial commitment (£85 million commitment to Freeline) made by Syncona Limited. This type of announcement, detailing fundraising, investment, or capital structure changes, aligns directly with the definition of a Capital/Financing Update. It is not a full annual report (10-K), an earnings release (ER), or a formal regulatory filing like a DVA or DIRS. Therefore, the most appropriate classification is CAP.
2018-06-19 English
Syncona Limited - Nightstar receives RMAT designation in Choroideremia
Regulatory Filings Classification · 95% confidence The document is a press release issued by Syncona Ltd regarding its portfolio company, Nightstar Therapeutics, announcing that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to their drug candidate NSR-REP1 for choroideremia. This type of announcement, detailing a specific regulatory milestone (RMAT designation) and providing context on the drug development, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement about a regulatory event and clinical progress, it fits best as an Earnings Release (ER) which often includes significant operational/regulatory updates, or potentially a Regulatory Filing (RNS) if it were less detailed. Given the structure (PR Newswire header, date, key announcement, detailed background, forward-looking statements), it functions as an initial release of significant news. However, the core content is a regulatory/clinical update, not a summary of financial performance for a period. Therefore, it is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement that doesn't fit the specific financial report categories (10-K, IR, ER). It is not a full report (like 10-K or IR), nor is it a management discussion (MDA) or a presentation (IP). It is a specific regulatory update.
2018-06-14 English
Syncona Limited - Syncona Limited Full Year Results 2018
Annual Report Classification · 95% confidence The document is titled 'Syncona Limited Full Year Results 2018' and covers the fiscal year ended 31 March 2018. It contains detailed financial performance metrics, including Net Asset Value (NAV), portfolio valuation tables, dividend declarations, and management commentary from the CEO and Chairman. While it is presented as a press release, it provides substantive financial data and analysis for the full fiscal year, fitting the definition of an Annual Report (10-K) or a comprehensive financial report. Given the depth of the financial tables and the reporting period, it is classified as an Annual Report. FY 2018
2018-06-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.